Exhaled nitric oxide during infancy as a risk factor for asthma and airway hyperreactivity

Daniel Chang\textsuperscript{1}, Weiguo Yao\textsuperscript{1}, Christina J. Tiller\textsuperscript{1}, Jeffrey Kisling\textsuperscript{1}, James E. Slaven\textsuperscript{2}, Zhangsheng Yu\textsuperscript{2}, Mark H. Kaplan\textsuperscript{1,3}, and Robert S. Tepper\textsuperscript{1}

\textsuperscript{1}Dept of Pediatrics, James Whitcomb Riley Hospital for Children, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
\textsuperscript{2}Dept of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA
\textsuperscript{3}Dept of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA

Abstract

Childhood asthma is often characterised by elevated exhaled nitric oxide (eNO), decreased lung function, increased airway reactivity and atopy; however, our understanding of when these phenotypic airway characteristics develop remains unclear. This study evaluated whether eNO, lung function, airway reactivity and immune characteristics during infancy are risk factors of asthma at age 5 years.

Infants with eczema, enrolled prior to wheezy illness (n=116), had eNO, spirometry, airway reactivity and allergen sensitisation assessed at entry to the study and repeated at age 5 years (n=90).

Increasing eNO at entry was associated with an increased risk of asthma (p=0.037) and increasing airway reactivity (p=0.015) at age 5 years. Children with asthma at 5 years of age had a greater increase in eNO between infancy and age 5 years compared with those without asthma (p=0.002). Egg sensitisation at entry was also associated with an increased risk of asthma (p=0.020), increasing eNO (p=0.002) and lower forced expiratory flows (p=0.029) as a 5 year-old.

Our findings suggest that, among infants at high risk for developing asthma, eNO early in life may provide important insights into the subsequent risk of asthma and its airway characteristics.

Introduction

Childhood asthma is often characterised by decreased lung function, heightened airway reactivity to bronchoconstrictors and elevated exhaled nitric oxide (eNO) \cite{1-3}. However, the relationship between these airway characteristics of asthma early in life and the development of childhood asthma remains unclear. Airway inflammation and lung function
measurements in infants can improve our understanding of the onset and progression of airway disease and may be useful in assessing the risk for developing asthma. While there have been relatively few longitudinal studies assessing airway physiology in infants prior to the onset of episodes of wheezing, the use of forced expiratory flows (FEF) has enabled a similar methodology to be applied longitudinally from infancy into adulthood and has provided the most important insights into the development of airway disease associated with childhood asthma [4-8].

eNO has been used as a biomarker for eosinophilic airway inflammation, but there has not been a longitudinal study of eNO from infancy, prior to onset of respiratory symptoms, into childhood. While several tidal breathing techniques have assessed eNO in infants [9, 10], our laboratory developed a technique to measure eNO in sedated infants under conditions of constant flow from elevated lung volume, a methodology similar to that used in older co-operative children and adults [11-13]. We previously reported that among a cohort of infants enrolled with eczema prior to the onset of wheezing increased eNO levels were associated with increased airway reactivity [14]. Those infants sensitised to egg and/or milk also had lower FEF and heightened airway reactivity. Our cohort has been reassessed at 5 years of age and we hypothesised that higher eNO, lower FEF and greater airway reactivity upon entry to the study would be associated with an increased risk of asthma at 5 years of age. We also hypothesised that those with asthma at age 5 years would have a greater increase in eNO, a smaller increase in FEF, and a greater increase in airway reactivity between infancy and follow-up when compared with subjects without asthma.

Methods

Subjects

Full-term infants and toddlers with eczema (n=116) were recruited from general paediatric clinics and advertisements, and were excluded if a history of wheezing or treatment with asthma medications was present [15]. Subjects were evaluated at entry to the study (median age of 10.7 months, range 2.6–19.1 months) and at 5 years of age (n=90). The study was approved by the Institutional Review Board (Indiana University School of Medicine, Indianapolis, IN, USA) and written parental consent was obtained.

Airway function

Exhaled nitric oxide—In infants, eNO was measured online at a constant expiratory flow from raised lung volume [11]. In 5-year-olds, eNO was measured online with a Niox eNO analyzer (Aerocrine, Solna, Sweden) [12, 13].

Spirometry—In infants, FEF were obtained using the raised volume technique [15]. Forced vital capacity (FVC) and FEF at 25–75% of FVC (FEF25-75%) were expressed as z-scores using normative data from our laboratory [15]. In 5-year-olds, spirometry was performed by subjects; FVC and FEF25-75% were expressed as z-scores using normative data from our laboratory [16].
Airway resistance and reactance—In 5-year-olds, airway resistance and reactance at 5 Hz ($R_5$; $X_5$) were obtained by impulse oscillometry (IOS) according to American Thoracic Society (ATS) and European Respiratory Society guidelines [17].

Airway reactivity—In infants, airway reactivity to increasing concentrations of inhaled methacholine (MCh) was assessed using FEF and quantified by PC$_{30}$ (the provocative concentration decreasing baseline FEF,$^{75\%}$ by 30%) [14].

In 5-year-olds, airway reactivity was assessed using IOS with increasing inhaled MCh (0.0625 mg·mL$^{-1}$; 0.25 mg·mL$^{-1}$; 1.0 mg·mL$^{-1}$; 4.0 mg·mL$^{-1}$; and 16 mg·mL$^{-1}$) using a five-breath technique according the ATS guidelines [18]. Airway reactivity was quantified by PC$_{40,R5}$ (the MCh dose that increased baseline $R_5$ by 40%) or the final MCh concentration inhaled [19, 20]. Following the last MCh dose and $R_5$ measurement, spirometry was repeated and the percentage decrease in forced expiratory volume in 1 s (FEV$_1$) from baseline (%ΔFEV$_1$) was used as an index of airway reactivity.

Immune characteristics

IgE—Venous blood was obtained at study entry and at 5 years of age to assess total IgE and allergen-specific IgE (egg white, milk, wheat, cat, house dust mite, Timothy grass, Bermuda grass, ragweed, Alternaria species and Mountain cedar; ImmuneTech Inc., Foster City, CA, USA). Subjects were considered allergen sensitised when the specific IgE level was >0.35 IU·mL$^{-1}$.

Cytokines—Peripheral blood mononuclear cells (PBMC) were isolated from the venous blood, cultured and stimulated with PMA (12-O-Tetradecanoylphorbol 13-acetate)/ionomycin to assess cytokine production (interleukin (IL)-4, IL-5, IL-13, IL-17, IL-9, IL-10 and interferon (IFN)$\gamma$) [21]. The ratios of individual cytokines to IFN$\gamma$ were employed to assess the balance between the T-helper cell (Th)2 and Th1 responses [21, 22].

Eczema

Eczema was doctor-diagnosed and the severity quantified using Scoring Atopic Dermatitis (SCORAD) at study entry and at age 5 years [23].

Respiratory history and asthma diagnosis

Histories for maternal cigarette smoking during pregnancy, cigarette smoking by household members or caregivers, as well as family (parent/sibling) history of asthma and/or allergy were obtained at study visits. In 5-year-olds, current asthma was defined as: 1) physician diagnosis of asthma at any time and a history of wheezing in the previous 12 months, or 2) the use of asthma medication (bronchodilators or inhaled corticosteroids) in the previous 12 months.

Statistical analysis

Patient characteristics (demographics, sensitisation variable, cytokines, eNO and lung functions) at entry were summarised for those with and without follow-up at 5 years of age, and compared using two-sample t-tests for continuous variables and Chi-squared test or
Fisher’s exact test for categorical variables. Total serum IgE and cytokine measurements were natural log transformed and satisfied the normal distribution assumption using Kolmogorov–Smirnov test.

Means of eNO, z-FEF_{25–75%} and airway reactivity were plotted at study entry and 5 years of age by asthma status at 5-years-old. T-tests were used to test the difference at each time point and the changes over time between the two groups. Using a logistic regression model we evaluated the individual associations between eNO, z-FEF_{25–75%} and airway reactivity at entry as predictors and the response variable of asthma status at 5 years of age, adjusting for age at entry to the study, race, sex and smoking during pregnancy. Results of each logistic regression model were reported as odds ratio with 95% confidence intervals and p-values.

Linear regression models were used to evaluate the association between each predictor of interest at entry (sensitisation to each individual allergen, total IgE, cytokines and SCORAD) and each response variable at 5 years of age (eNO, z-FEF_{25–75%} and %ΔFEV₁) with adjustments for age at entry to the study, race, sex and smoking during pregnancy. Results of each linear regression model were presented as a coefficient estimate with 95% confidence interval and p-value. For the cytokine production, we standardised using standard deviation as log(cytokine+1)/\text{SD} × (cytokine+1); the estimated coefficient represents the change in mean response or log odds ratio corresponding to one standard deviation increase in the predictor. All analyses were performed using SAS v9.3 (SAS Institute, Cary, NC, USA).

Results

Subjects
Of 116 subjects recruited at entry, 26 subjects were lost to follow-up at 5 years of age (table 1). Those who did not have follow-up were predominantly female (70% versus 47%; p=0.035), non-Caucasian (76% versus 48%; p=0.017), more likely to have history of maternal smoking during pregnancy (25% versus 7%; p=0.013) and less likely to have family asthma (69% versus 86.5%; p=0.048). Among 5-year-olds, 61 (68%) out of 90 subjects had asthma.

Exhaled nitric oxide
Subjects with asthma at 5 years of age had significantly higher eNO at study entry as infants prior to any wheezing (eNO difference: 3.5 ppb, 95% CI 0.12–6.84 ppb; p=0.035), as well as a significantly higher eNO as 5-year-olds compared with subjects without asthma (eNO difference: 10.8 ppb, 95% CI 1.53–19.99 ppb; p=0.023). In addition, the increase in eNO between infancy and follow-up at 5 years of age was significantly greater for subjects with asthma as 5-year-olds compared with subjects without asthma (slope difference: 7.3, 95% CI 6.9–7.7; p=0.001) (fig. 1). Higher eNO at study entry was significantly associated with a greater risk of asthma at 5 years of age; each ppb increase in eNO at entry was associated with an increased risk of asthma at 5 years of age (OR 1.13, 95% CI 1.01–1.26; p=0.037). Increasing eNO at study entry was also significantly associated with greater airway reactivity at 5 years of age; each ppb increase in eNO at study entry was associated with a
greater decrease in FEV$_1$ during the MCh challenge as 5-year-olds (coefficient=0.76%, 95% CI 0.71–0.85%; p=0.015).

**Forced expiratory flows**

Subjects with asthma at 5 years of age had a statistically nonsignificant lower z-FEF$_{25–75\%}$ at entry to the study (z-score difference: 0.46, 95% CI −0.01–0.93; p=0.053) and had significantly lower z-FEF$_{25–75\%}$ as 5-year-olds compared with subjects without asthma (z-score difference: 0.78, 95% CI 0.16–1.39; p=0.014). The increase in z-FEF$_{25–75\%}$ between infancy and follow-up at 5 years of age was smaller, but statistically nonsignificant, between subjects with asthma as 5-year-olds compared with subjects without asthma (slope difference: 0.31, 95% CI −0.01–0.60; p=0.061) (fig. 2). Higher z-FEF$_{25–75\%}$ at study entry was statistically nonsignificantly associated with a lower risk of asthma as a 5-year-old (OR 0.6, 95% CI 0.36–1.00; p=0.051). Lower z-FEF$_{25–75\%}$ at study entry was significantly associated with lower z-FEF$_{25–75\%}$ (OR 0.34, 95% CI 0.06–0.61; p=0.018) and greater airway reactivity (%ΔFEV$_1$) as a 5-year-old (OR 5.15, 95% CI 0.39–9.92; p<0.035).

**Airway reactivity**

Subjects with asthma as 5-year-olds were no different from nonasthmatic subjects in terms of airway reactivity at entry to the study (PC$_{30}$) (PC$_{30}$ difference: 0.04, 95% CI −0.72–0.80; p=0.904); however, they had greater airway reactivity at 5 years of age compared with subjects without asthma (%ΔFEV$_1$ difference: 24.2%, 95% CI 7.6–40.8%; p=0.005). The increase in airway reactivity between infancy and follow-up at 5 years of age was significantly greater for subjects with asthma compared with subjects without asthma (slope difference: 16.1, 95% CI 5.54–26.70; p=0.004) (fig. 3). Greater airway reactivity (lower PC$_{30}$) at study entry was not associated with an increased risk for asthma at 5 years of age (OR 0.98, 95% CI 0.66–1.44; p=0.899), nor with greater airway reactivity (% ΔFEV$_1$) as a 5-year-old (OR 4.34, 95% CI −0.89–9.57; p=0.329).

**Infant immune characteristics and SCORAD**

Upon entry to the study, sensitisation to egg (OR 20.8, 95% CI 1.61–250.00; p=0.020) and higher SCORAD (OR 1.095, 95% CI 1.01–1.19; p<0.026) were associated with a significant risk for asthma at 5 years of age. There were no significant associations between any other specific allergen sensitisations, total IgE, or cytokine production by stimulated PBMCs with an increased risk for asthma at 5 years of age. Infant sensitisation to egg, higher total serum IgE, and higher IL-9 and IL-17 production were all significantly associated with higher eNO at 5 years of age (table 2). Sensitisation to egg and higher total IgE, as well as higher IL-17 and SCORAD, were all associated with lower FEF$_{25–75\%}$ at 5 years of age. There were no associations between immune characteristics in infants and airway reactivity at 5 years of age.

**Discussion**

In our selected cohort of infants with eczema, we found that increasing eNO prior to any episodes of wheezing, was associated with an increased risk of asthma and increasing airway reactivity at 5 years of age. Those with asthma at 5 years of age also had higher eNO.
at study entry, and a greater increase in eNO between infancy and follow-up compared with those without asthma. Egg sensitisation and increasing total IgE during infancy were also associated with an increased risk of asthma, higher eNO and lower FEF as a 5-year-old. Our findings suggest that, among infants at high risk of developing asthma, eNO levels early in life may provide important insights into the subsequent risk of asthma and its airway characteristics. In addition, our results emphasise that strategies to modulate the development of preschool asthma may require interventions very early in life.

Our study is the first to demonstrate that higher eNO measured prior to episodes of wheezing is not only associated with an increased risk of asthma as a preschool child, but is also associated with greater airway reactivity. Our current findings are consistent with our earlier report for this cohort that increasing eNO was associated with increasing airway reactivity when assessed at entry to study [14]. In an unselected birth cohort, Latzin et al. [9] reported that higher eNO at 1 month of age was associated with an increased risk of severe respiratory symptoms in the first year of life among infants of atopic mothers or mothers who smoked tobacco during pregnancy. However, in another unselected cohort, Gabriele et al. [10] reported that eNO measured at 6 months of age was only minimally associated with an increase in the risk of wheezing in the second year of life. Recently, Singer et al. [24] reported that among preschool children with recurrent respiratory symptoms, those with higher eNO (off-line) had an increased risk of asthma at school age. However, Deley et al. [25] reported that among infants with recurrent wheezing, elevated eNO was associated with lower FEF and greater bronchodilator responsiveness at 6-month follow-up. Evaluating a group of infants with recurrent wheezing, Kotaniemi-Syrjanen et al. [26] found that increased eNO was associated with heightened airway reactivity. Cumulatively, these studies suggest that measuring eNO early in life may provide important insights into the subsequent risk of asthma and its airway characteristics.

In our current study, lower FEF during infancy were statistically nonsignificantly associated with a higher risk of developing asthma as a 5-year-old (p=0.051), and those with asthma had a statistically nonsignificant smaller increase in FEF between infancy and follow-up compared with those without asthma (p=0.061). Our results support the concept that the deficit in airway function associated with childhood asthma is present very early in life [5, 27, 28], and they are consistent with those of Bisgaard et al. [8] who followed up a selected high-risk cohort at 7 years of age. Our study suggests that these relationships are present even earlier, at the preschool age. As neither study evaluated post-bronchodilator spirometry during infancy and at follow-up, it remains unclear whether the lower flows early in life, as well as the worsening with time, are related to fixed, non-reversible airway dysfunction or increased airway tone. At 4-year follow-up of our cohort, the lower spirometry in subjects with asthma was no longer present following a bronchodilator [4]. We also found that lower spirometry during infancy was associated with a greater bronchodilator response at 4 years of age, which suggested an increase in airway tone, rather than fixed airway obstruction or abnormal lung growth. It remains important to determine whether decrements in airway function early in life and greater decrements in childhood represent changes in lung growth, worsening fixed airway disease or increased airway tone, as these distinctions are critical in determining the potential importance of early intervention and evaluating outcomes.
In our study, we did not find association between airway reactivity during infancy and risk of asthma at 5 years of age. Our results differ from those of Bisgaard et al. [8], who found that increased sensitivity to MCh early in life was associated with an increased risk of asthma at 7 years of age. This difference may result from differences in the selection of high-risk subjects, the smaller number of subjects in our study and the differing methodologies used to assess airway reactivity. The only other longitudinal study of airway reactivity from early in life evaluated an unselected cohort; however, the relationship of airway reactivity in infancy to asthma or respiratory symptoms at follow-up was not consistent among follow-up studies [28, 29].

Egg sensitisation as an infant was the most important risk factor for asthma, higher eNO, lower spirometry and atopy at 5 years of age, while total serum IgE and SCORAD were less consistent and less important than egg sensitisation. These findings are consistent with our previous report that food sensitisation during infancy was associated with asthma and lung function at 4 years of age [4], and consistent with other cohort studies demonstrating the importance of food allergies early in life, while aeroallergen sensitisation does not become important until several years of age [30-33].

We did not find that cytokine production by stimulated PBMCs was associated with asthma at 5 years of age, which contrasts with our previous findings that increasing IL-4 and IL-10 as an infant was associated with an increased risk of asthma at 4 years of age [4]. However, we did find that increasing IL-17 production at entry to the study was associated with lower lung function and higher eNO at 5 years of age. This finding is consistent with studies finding increased IL-17 in asthmatic airways, and the ability of IL-17 to promote airway hyperresponsiveness [34-37]. In addition, in children with asthma, serum IL-17 levels were positively correlated with eNO [38]. IL-17 has been proposed to be an effector cytokine that mediates steroid resistant pulmonary inflammation [39]. The function of IL-17 in infants has not been examined and our study suggests it might have unique functions early in life.

There are several limitations to our study. Our subjects had eczema, which may explain our high prevalence of asthma (68%) at 5 years of age; therefore, our results cannot be extrapolated to a general population. In addition, our subjects were not a birth cohort; subjects who were older at entry to the study had gone longer without any wheezing illness. We adjusted our analysis for age at entry, which did not have a significant effect; therefore, we do not believe this created a sampling bias that affected the interpretation of our results. We found that severity of eczema at study entry was associated with an increased risk of asthma at 5 years of age, which is consistent with previous studies [20, 40]; however, we may have underestimated this association. For infants, SCORAD was assessed at the time of lung function testing and not at the time of eczema diagnosis; therefore, subjects were already receiving treatment for their dermatitis. We found that 22 subjects did not perform acceptable spirometry at 5 years of age; however, this is consistent with assessment at this young age [17]. For the same reason, we assessed airway reactivity using IOS, as well as using the change in spirometry from baseline to the last MCh dose. Including spirometry was important as an outcome, as it proved to be more sensitive than oscillometry in discriminating baseline airway function and airway reactivity in those with and without asthma at 5 years of age, which is consistent with several studies of children [20, 40].
In summary, we found that eNO obtained prior to any episodes of wheezing was associated with an increased risk of asthma and/or altered airway function as a preschool child. Those with asthma at 5 years of age had a greater increase in eNO and airway reactivity between infancy and follow-up compared with those without asthma. These findings indicate that the airway characteristics of asthma are present very early in life and progress by 5 years of age. eNO and spirometric measurements during infancy may be useful in evaluating strategies to modify the progression of asthma early in life.

Acknowledgments

Support statement: Supported by NIH grant numbers HL080071, AI070448 and AI057459.

References


Exhaled nitric oxide (eNO) at study entry and at 5 years of age. Subjects with asthma at 5 years of age had significantly higher eNO at entry to the study as infants prior to any wheezing (eNO difference: 3.5 ppb, 95% CI 0.12–6.84 ppb; p=0.035), as well as a significantly higher eNO at 5 years of age compared with subjects without asthma (eNO difference: 10.8 ppb, 95% CI 1.53–19.99 ppb; p=0.023). In addition, the increase in eNO between infancy and 5-year-old follow-up was significantly greater for subjects with asthma at 5 years of age compared with subjects without asthma (slope difference: 7.3, 95% CI 6.9–7.7; p=0.001). Data are presented as mean±se. The model was adjusted by age at entry to the study, sex, race and smoking during pregnancy.
FIGURE 2.
Z-score for forced expiratory flows at 25–75% of forced vital capacity (z-FEF\textsubscript{25–75%}) at study entry and at 5 years of age. Subjects with asthma at 5 years of age had a statistically nonsignificant lower z-FEF\textsubscript{25–75%} at entry to the study as infants prior to any wheezing (z-score difference: 0.46, 95% CI −0.01–0.93; p=0.053), and had significantly lower z-FEF\textsubscript{25–75%} at 5 years of age compared with subjects without asthma (z-score difference: 0.78, 95% CI 0.16–1.39; p=0.014). In addition, the increase in z-FEF\textsubscript{25–75%} between infancy and 5-year-old follow-up was smaller, but statistically nonsignificant, for subjects with asthma at 5 years of age compared with subjects without asthma (slope difference: 0.31, 95% CI −0.01–0.60; p=0.061). Data are presented as mean±SE. The model was adjusted by age at entry to the study, sex, race and smoking during pregnancy.
FIGURE 3.
Airway responsiveness at study entry and at 5 years of age. Subjects with asthma at 5 years of age had no differences in airway reactivity at entry to the study (the provocative concentration decreasing baseline forced expiratory flow at 75% of forced vital capacity by 30% (PC\textsubscript{30})) (PC\textsubscript{30} difference: 0.04, 95% CI −0.72–0.80; p=0.904), but greater airway reactivity at 5 years of age (percentage decrease in forced expiratory volume in 1 s (FEV\textsubscript{1}) from baseline (%ΔFEV\textsubscript{1})) compared with subjects without asthma (%ΔFEV\textsubscript{1} difference: 24.2%, 95% CI 7.6–40.8%; p=0.005). In addition, the increase in airway reactivity between infancy and 5-year-old follow-up was significantly greater for subjects with asthma compared with subjects without asthma (slope difference: 16.1, 95% CI 5.54–26.70; p=0.004). Data are presented as mean±SE. The model was adjusted by age at entry to the study, sex, race and smoking during pregnancy.
## TABLE 1

|                   | All       | LTFU     | Followed up | p-value *
|-------------------|-----------|----------|-------------|---------
| **Subjects n**    | 116       | 26       | 90          |         |
| **Age months**    | 10.66±4.62| 9.90±4.64| 10.92±4.61  | 0.301   |
| **Sex (female)**  | 63 (52.5) | 21 (70.0)| 42 (46.7)   | 0.035   |
| **Race (white)**  | 53 (45.3) | 7 (24.1) | 46 (52.3)   | 0.009   |
| **Smoking during pregnancy** | 13 (11.0) | 7 (25.0) | 6 (6.7)     | 0.013   |
| **Family history of asthma** | 97 (82.2) | 20 (69.0)| 77 (86.5)   | 0.048   |
| **eNO ppb**       | 13.1±6.82 | 10.9±5.60| 13.8±7.03   | 0.060   |
| **z-FEF_{25-75%}**| −0.85±1.10| −1.15±1.28| −0.77±1.03  | 0.126   |
| **Egg allergen sensitisation** | 19 (16.7) | 2 (7.7)  | 17 (19.3)   | 0.234   |
| **Aeroallergen sensitisation** § | 31 (27.2) | 7 (26.9) | 24 (27.3)   | 0.999   |
| **Total IgE +**   | 2.20±1.67 | 1.94±1.33| 2.27±1.76   | 0.375   |
| IL-4/IFNγ §       | 0.74±0.72 | 0.70±0.90| 0.76±0.65   | 0.765   |
| IL-5/IFNγ §       | 0.85±0.81 | 0.84±0.78| 0.90±0.90   | 0.744   |
| IL-9/IFNγ §       | 0.72±0.82 | 0.86±0.90| 0.68±0.79   | 0.336   |
| IL-10/IFNγ §      | 0.54±0.55 | 0.60±0.79| 0.52±0.45   | 0.598   |
| IL-13/IFNγ §      | 1.02±0.89 | 1.17±0.91| 0.97±0.89   | 0.325   |
| IL-17/IFNγ §      | 1.13±0.82 | 1.36±0.86| 1.05±0.80   | 0.098   |
| **SCORAD**        | 10.28±7.70| 9.59±8.51| 10.49±7.47  | 0.598   |

Data are presented as mean±SD or n (%), unless otherwise stated. Bold font indicates statistical significance. LTFU: lost to follow-up; eNO: exhaled nitric oxide; z-FEF_{25–75%}: z-score for forced expiratory flows at 25–75% of forced vital capacity; IL: interleukin; IFN: interferon; SCORAD: scoring atopic dermatitis.

* p-values are for comparison between LTFU and patients who were followed at 5 years of age, two-sample T-tests were used for continuous variables and Fisher’s exact test for categorical variables;

§ presence of sensitisation to at least one of the following allergens: Timothy grass, Bermuda grass, short ragweed, Alternaria species and/or Mountain cedar;

+ total serum IgE expressed as the log transformed value;

§ standardised as log(cytokine+1)/\sigma × (cytokine+1).
### TABLE 2

Immune characteristics and SCORAD at study entry as predictors of airway function at 5 years of age

<table>
<thead>
<tr>
<th>Parameter at study entry</th>
<th>eNO Estimate (95% CI)</th>
<th>p-value</th>
<th>z-FEF&lt;sub&gt;25–75%&lt;/sub&gt; Estimate (95% CI)</th>
<th>p-value</th>
<th>%ΔFEV&lt;sub&gt;1&lt;/sub&gt; Estimate (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egg allergen sensitisation</td>
<td>16.7 (6.48–26.94)</td>
<td>0.002</td>
<td>−0.7 (−1.44–−0.08)</td>
<td>0.029</td>
<td>−6.8 (−20.28–6.63)</td>
<td>0.313</td>
</tr>
<tr>
<td>Aeroallergen sensitisation</td>
<td>2.4 (−8.51–13.26)</td>
<td>0.664</td>
<td>0.5 (−0.15–1.13)</td>
<td>0.132</td>
<td>3.8 (−8.02–15.67)</td>
<td>0.518</td>
</tr>
<tr>
<td>Total IgE</td>
<td>3.4 (0.91–5.96)</td>
<td>0.008</td>
<td>−0.2 (−0.34−0.03)</td>
<td>0.021</td>
<td>−1.3 (−4.40–1.77)</td>
<td>0.395</td>
</tr>
<tr>
<td>IL-4/IFN&lt;sub&gt;γ&lt;/sub&gt;</td>
<td>3.1 (−4.71–10.94)</td>
<td>0.428</td>
<td>−0.2 (−0.63–0.31)</td>
<td>0.499</td>
<td>−3.1 (−10.76–4.62)</td>
<td>0.424</td>
</tr>
<tr>
<td>IL-5/IFN&lt;sub&gt;γ&lt;/sub&gt;</td>
<td>4.1 (−2.75–10.99)</td>
<td>0.234</td>
<td>−0.1 (−0.55–0.27)</td>
<td>0.485</td>
<td>−3.0 (−9.66–3.63)</td>
<td>0.364</td>
</tr>
<tr>
<td>IL-9/IFN&lt;sub&gt;γ&lt;/sub&gt;</td>
<td>6.2 (0.12–12.30)</td>
<td>0.046</td>
<td>−0.2 (−0.61–0.12)</td>
<td>0.181</td>
<td>0.4 (−5.70–6.53)</td>
<td>0.891</td>
</tr>
<tr>
<td>IL-10/IFN&lt;sub&gt;γ&lt;/sub&gt;</td>
<td>8.7 (−2.42–19.89)</td>
<td>0.122</td>
<td>−0.3 (−1.01–0.32)</td>
<td>0.306</td>
<td>−7.3 (−18.01–3.49)</td>
<td>0.180</td>
</tr>
<tr>
<td>IL-13/IFN&lt;sub&gt;γ&lt;/sub&gt;</td>
<td>4.5 (−1.53–10.46)</td>
<td>0.141</td>
<td>−0.2 (−0.54–0.16)</td>
<td>0.281</td>
<td>1.25 (−4.50–7.00)</td>
<td>0.663</td>
</tr>
<tr>
<td>IL-17/IFN&lt;sub&gt;γ&lt;/sub&gt;</td>
<td>8.6 (2.33–14.80)</td>
<td>0.008</td>
<td>−0.4 (−0.77−0.01)</td>
<td>0.044</td>
<td>4.0 (−2.98–10.98)</td>
<td>0.253</td>
</tr>
<tr>
<td>SCORAD</td>
<td>0.53 (−0.10–1.15)</td>
<td>0.097</td>
<td>−0.04 (−0.08−0.002)</td>
<td>0.037</td>
<td>−0.12 (−0.97–0.74)</td>
<td>0.780</td>
</tr>
</tbody>
</table>

Bold font indicates statistical significance. SCORAD: Scoring Atopic Dermatitis; eNO: exhaled nitric oxide; z-FEF<sub>25–75%</sub>: z-score for forced expiratory flows at 25–75% of forced vital capacity; %ΔFEV<sub>1</sub>: percentage change in forced expiratory volume in 1 s between baseline and after final methacholine dose when reaching PC<sub>20</sub>R<sub>5</sub> (the methacholine dose that increased baseline R<sub>5</sub> by 40%); IL: interleukin; IFN: interferon.

# presence of at least one positive sensitisation to the following allergens: Timothy grass, Bermuda grass, Short ragweed, Alternaria species and Mountaincedar;

¶ total serum IgE was expressed as the log transformed value;

+ standardised as log(cytokine+1)/SD × (cytokine+1). The model was adjusted by age at entry to the study, sex, race and smoking during pregnancy.